程博

摘要：目的 探讨分析对风痰阻络型急性缺血性脑卒中患者采用半夏白术天麻汤联合依达拉奉进行治疗的临床疗效。方法 选取本院2020年1月到2021年1月收治的74例风痰阻络型急性缺血性脑卒中患者开展本次试验研究，将所有患者按照双盲法分组。其中单独予以依达拉奉治疗的37例为参照组，联合半夏白术天麻治疗的37例为研究组，观察两组的治疗情况。结果 比较两组的治疗效果以及治疗后的神经功能缺损评分，研究组均优于参照组（P<0.05）。结论 根据本次研究的结果可以确认，对风痰阻络型急性缺血性脑卒中患者采用半夏白术天麻汤联合依达拉奉进行治疗的临床疗效十分确切，值得在临床上大力推广。

关键词：风痰阻络型;急性缺血性脑卒中;半夏白术天麻汤;依达拉奉;临床疗效

[Abstract] Objective To explore and analyze the clinical efficacy of Banxia Baizhu Tianma decoction combined with edaravone in the treatment of acute ischemic stroke with wind phlegm blocking collaterals. Methods 74 patients with acute ischemic stroke of wind phlegm Blocking Collaterals treated in our hospital from January 2020 to January 2021 were selected to carry out this experimental study. All patients were divided into double-blind groups. Among them，37 cases treated with edaravone alone as the reference group and 37 cases treated with Pinellia Atractylodes Rhizoma Gastrodia elata as the study group. Results the treatment effect and neurological deficit score of the two groups were compared. The study group was better than the reference group（P < 0.05）. Conclusion according to the results of this study，it can be confirmed that the clinical efficacy of Banxia Baizhu Tianma decoction combined with edaravone in the treatment of acute ischemic stroke patients with wind phlegm blocking collaterals is very accurate，which is worthy to be vigorously promoted in clinical practice.

【key words】wind phlegm Blocking Collaterals type;Acute ischemic stroke;Banxia Baizhu Tianma Decoction;Edaravone;Clinical efficacy

急性缺血性腦卒中属于神经内科较为常见的一种疾病，该病具有很大的危险性，需要在患者发病后6小时内对患者开展溶栓治疗，才可以有效挽救患者的生命，防止患者出现后遗症，并改善患者的预后【1】。然而，由于时间窗的时间较短，大多数患者往往已经错过了这一时间，这时对患者的治疗难度较大，通常是采用药物治疗控制患者的病情【2】。但是，常规西药的治疗效果不佳，难以取得令人满意的治疗效果。因此，本文旨在探讨分析对风痰阻络型急性缺血性脑卒中患者采用半夏白术天麻汤联合依达拉奉进行治疗的临床疗效。

1 资料和方法

1.1一般资料